

Pediatric Vaccines Market, Doses, Immunization, Cases and Forecast: Worldwide Analysis

<https://marketpublishers.com/r/P30680D4053EN.html>

Date: July 2017

Pages: 0

Price: US\$ 1,700.00 (Single User License)

ID: P30680D4053EN

Abstracts

Global Pediatric Vaccines Market is expected to cross US\$ 40 Billion by the year 2022. Our analysis found that the combination and pneumococcal vaccines was the two leading vaccines segment in 2017 and they continue to dominate the market in future years as well. The market of Combos (Combination vaccines) is thriving as most of the parents believed that if all these vaccines were given separately, than each child would have to take a large number of injections.

By the Year 2022, 500 Million Pediatrics will be get Immunization

Our research found that around 500 million infants get immunization by the year 2022 owing to rising concern against vaccine-preventable diseases and growing awareness. This report covers the past and present scenario and the growth prospects of the infants' vaccine (Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap, Polio, Haemophilus influenzae type B, Rotavirus, Varicella, Combination) Vaccines market across the world for the period of 2011-2022.

Globally 600 Million Doses of Vaccines will be Administrated in Pediatrics

Our study indicates that that around the globe nearly 600 million doses of vaccines will be administrated in infants by the year 2022 which will be nearly five times the number of influenza doses administered. The number of DTap doses administered in infants is forecast to increase over the years and will cross 50 Million by the year 2022. Report covers detailed information on all the 11 vaccines (Pneumococcal, Rotavirus, Meningococcal, DTap, MMR, Polio, Hepatitis, Varicella, Haemophilus influenzae type B, Influenza, Combination) Vaccines Doses of Vaccines Administered and Forecast.

Pediatric Vaccines Market, Doses, Immunization, Cases and Forecast: Worldwide Analysis is the 2nd edition report published by Renub Research on Pediatric Vaccines. This 199 page market research report with 93 Figures and 30 Tables provides data and analysis on Global Pediatric Vaccines Market, Infants Immunized, Number of Vaccine Doses Administered in Pediatric (Infant) (Disease wise) & Key Players.

Vaccine Has Been Extensively Studied From 3 Major Points

1. Global Pediatric (Infant) Vaccines (Disease wise) Market & Forecast (2011 – 2022)
2. Pediatric (Infants) Immunized (Disease wise) & Forecast (2011 – 2022)
3. Doses of Vaccines Administered in Pediatric (Infant) (Disease wise) & Forecast (2011 – 2022)

11 Vaccines Studied in the Report are as Follows

1. Influenza
2. MMR (Measles, Mumps, and Rubella)
3. Pneumococcal
4. Meningococcal
5. Hepatitis
6. DTap (Diphtheria, Tetanus, Pertussis)
7. Haemophilus influenzae type B
8. Polio
9. Rotavirus
10. Varicella
11. Combination Vaccine

Companies Vaccines Sales and Forecast

1. GlaxoSmithKline, plc Sales & Forecast (2011 – 2022)
2. Merck & Co. Sales & Forecast (2011 – 2022)
3. Sanofi Pasteur's Sales & Forecast (2011 – 2022)
4. Pfizer, Inc.'s Sales & Forecast (2011 – 2022)
5. Others Vaccines

Key Questions Answered In This Report

What will be the market size of Global Pediatric Vaccine by the year 2022?

What are the Key drivers for Pediatric Vaccines Market?

What are the challenges to Infant Vaccines market?

Who are the key players in Pediatric Vaccines market?

What products are in key players Pipeline?

Contents

1 RESEARCH FINDINGS

2 GLOBAL - PEDIATRIC (INFANT) VACCINES MARKET AND FORECAST

3 GLOBAL – PEDIATRIC (INFANT) VACCINES MARKET SHARE AND FORECAST

4 GLOBAL – PEDIATRIC (INFANT) IMMUNIZED AND FORECAST

5 GLOBAL – PEDIATRIC (INFANT) IMMUNIZED SHARE AND FORECAST

6 GLOBAL – DOSES OF PEDIATRIC (INFANT) VACCINES ADMINISTERED AND FORECAST

7 GLOBAL – DOSES OF VACCINES ADMINISTERED TO PEDIATRIC (INFANT) SHARE AND FORECAST

8 GLOBAL – VACCINE COMPANIES MARKET SHARE AND FORECAST

9 DISEASE WISE – VACCINES MARKET AND FORECAST

9.1 Influenza – Pediatric (Infant) Vaccines Market and Forecast

9.2 MMR (Measles, Mumps, and Rubella Vaccine) – Pediatric Vaccines Market and Forecast

9.3 Pneumococcal – Pediatric Vaccines Market and Forecast

9.4 Meningococcal – Pediatric Vaccines Market and Forecast

9.5 Hepatitis – Pediatric Vaccines Market and Forecast

9.6 DTaP – Pediatric Vaccines Market and Forecast

9.7 Haemophilus Influenzae Type B (HIB) – Vaccines Market and Forecast

9.8 Combos (Combination) – Vaccines Market and Forecast

9.9 Polio – Vaccines Market and Forecast

9.1 Rotavirus – Vaccines Market and Forecast

9.11 Varicella – Vaccines Market and Forecast

10 DISEASE WISE – INFANTS IMMUNIZED NUMBERS AND FORECAST

10.1 Influenza – Number of Infants Immunized and Forecast

- 10.2 MMR – Number of Pediatric (Infants) Immunized and Forecast
- 10.3 Pneumococcal – Number of Infants Immunized and Forecast
- 10.4 Meningococcal – Number of Infants Immunized and Forecast
- 10.5 Hepatitis – Number of Infants Immunized and Forecast
- 10.6 DTaP – Number of Infants Immunized and Forecast
- 10.7 Hib (Haemophilus Influenzae Type B) – Number of Infants Immunized and Forecast
- 10.8 Combos (Combination Vaccines) – Number of Infants Immunized and Forecast
- 10.9 Polio – Number of Infants Immunized and Forecast
- 10.1 Rotavirus – Number of Infants Immunized and Forecast
- 10.11 Varicella – Number of Infants Immunized and Forecast

11 DISEASE WISE – DOSES OF VACCINES ADMINISTERED AND FORECAST

- 11.1 Influenza – Doses of Infant Vaccines Administered and Forecast
- 11.2 MMR – Doses of Infant Vaccines Administered and Forecast
- 11.3 Pneumococcal – Doses of Infant Vaccines Administered and Forecast
- 11.4 Meningococcal – Doses of Infant Vaccines Administered and Forecast
- 11.5 Hepatitis – Doses of Infant Vaccines Administered and Forecast
- 11.6 DTaP – Doses of Infant Vaccines Administered and Forecast
- 11.7 Hib (Haemophilus Influenzae Type B) – Doses of Infant Vaccines Administered and Forecast
- 11.8 Polio – Doses of Infant Vaccines Administered and Forecast
- 11.9 Rotavirus – Doses of Infant Vaccines Administered and Forecast
- 11.1 Varicella – Doses of Infant Vaccines Administered and Forecast

12 DISEASE WISE - IMMUNIZATION PROFILE

- 12.1 Immunization Coverage (%) in Infants (2005 – 2015)
- 12.2 Global Immunization Profile (2011 – 2015)
- 12.3 Regional Immunization Profile (2001 – 2015)
 - 12.3.1 Measles – Number of Cases Reported
 - 12.3.2 Mumps – Number of Cases Reported
 - 12.3.3 Rubella – Number of Cases Reported
 - 12.3.4 Rubella (CRS) – Number of Cases Reported
 - 12.3.5 Diphtheria – Number of Cases Reported
 - 12.3.6 Tetanus (Neonatal) – Number of Cases Reported
 - 12.3.7 Tetanus (Total) – Number of Cases Reported
 - 12.3.8 Pertussis – Number of Cases Reported

- 12.3.9 Polio – Number of Cases Reported
- 12.3.10 Yellow Fever – Number of Cases Reported
- 12.3.11 Japanese encephalitis – Number of Cases Reported, 2006 - 2015

13 VACCINES KEY PLAYERS SALES AND FORECAST

- 13.1 GlaxoSmithKline, plc.'s Vaccines Sales and Forecast
- 13.2 Merck & Co. Vaccines Sales and Forecast
- 13.3 Sanofi Pasteur's Vaccines Sales and Forecast
- 13.4 Pfizer, Inc.'s Vaccines Sales and Forecast
- 13.5 Others Vaccines Sales and Forecast

14 VACCINES – PRODUCTS AND PIPELINE

- 14.1 GSK Vaccine Product Pipeline
- 14.2 Merck Vaccine Product Pipeline
- 14.3 Sanofi Vaccine Product Pipeline
- 14.4 Pfizer Vaccine Product Pipeline

15 TOP MERGERS AND ACQUISITIONS IN THE VACCINE INDUSTRY

16 VACCINES AND REGULATOR'S INTERVENTIONS

- 16.1 Making and Meeting Standards of Quality and Safety
- 16.2 Vaccine Funding

17 VACCINE MARKET DRIVERS

- 17.1 Inclusion in National Immunization Schedule
- 17.2 Growing Immunization Coverage for HPV Vaccines
- 17.3 Increase in Prevalence of Infectious Diseases
- 17.4 Global Immunization Vision and Strategy (GIVS)
- 17.5 GAVI Model Fuelling Vaccine Manufacturers
 - 17.5.1 The Partnership Model
 - 17.5.2 The Business Model
- 17.6 Increasing Vaccine Availability in United States
- 17.7 The Vaccine Safety Data link Project
- 17.8 The Vaccine Injury Compensation Program
- 17.9 Transforming of Vaccine Technologies

- 17.1 Global Vaccine Action Plan by WHO (2011 - 2020)
- 17.11 Continuous Focus on Effective Communication Strategies

18 VACCINES MARKET CHALLENGES

- 18.1 Hurdles to Optimal use of Licensed Vaccines
 - 18.1.1 Technical Obstacles
 - 18.1.2 Economic Obstacles
 - 18.1.3 Cultural Obstacles
- 18.2 Complexity of Vaccine Development & Approval System Thwarts Product Development
 - 18.2.1 Legal Obstacles
 - 18.2.2 General Technical Barriers
 - 18.2.3 Economic Barriers
 - 18.2.4 Regulatory Barriers
- 18.3 Shortening the Timeline for Vaccine Development
- 18.4 Refusal/Resistance to Vaccination
 - 18.4.1 Vaccine Adverse Event Reporting System
- 18.5 Vaccine Shortages and Delays
- 18.6 Obstacles in Vaccine Research & Development
- 18.7 Barriers to New Entrants in the Vaccines Market

LISTS OF TABLES

- Table 3-1: Global – Pediatric (Infant) Vaccines Market Share (Percent), 2011 - 2016
- Table 3-2: Global – Forecast for Pediatric (Infant) Vaccines Market Share (Percent), 2017 - 2022
- Table 5-1: Global – Pediatric (Infant) Immunized Share (Percent), 2011 – 2016
- Table 5-2: Global – Forecast for Pediatric (Infant) Immunized Share (Percent), 2017 – 2022
- Table 7-1: Global – Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2011 - 2016
- Table 7-2: Global – Forecast for Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2017 - 2022
- Table 12-1: Worldwide – Number of Reported Cases, 2011 – 2015
- Table 12-2: Measles – Number of Cases Reported, 2001 – 2015
- Table 12-3: Mumps – Number of Cases Reported, 2001 - 2015
- Table 12-4: Rubella – Number of Cases Reported, 2001 - 2015
- Table 12-5: Rubella (CRS) – Number of Cases Reported, 2001 - 2015
- Table 12-6: Diphtheria – Number of Cases Reported, 2001 - 2015

Table 12-7: Tetanus (Neonatal) – Number of Cases Reported, 2001 – 2015

Table 12-8: Tetanus (Total) – Number of Cases Reported, 2001 - 2015

Table 12-9: Pertussis – Number of Cases Reported, 2001 - 2015

Table 12-10: Polio – Number of Cases Reported, 2001 - 2015

Table 12-11: Yellow Fever – Number of Cases Reported, 2001 - 2015

Table 12-12: Japanese encephalitis – Number of Cases Reported, 2006 - 2015

Table 14-1: Merck Vaccine Product Pipeline

Table 14-2: Sanofi Vaccine Product Pipeline

Table 14-3: Pfizer Vaccine Product Pipeline

Table 15-1: Vaccine Mergers & Acquisitions

Table 17-1: United States Immunization Schedule

Table 17-2: Afghanistan Immunization Schedule

Table 17-3: Norway Immunization Schedule

Table 17-4: India Immunization Schedule

Table 17-5: Vietnam Immunization Schedule

Table 17-6: Worldwide – Total Future Deaths Averted through Vaccination (Million), 2011 – 2020

Table 17-7: Goal-Level Indicators, 2015 & 2020

Table 17-8: Improvement Strategies or Requirements – the Joint Commission and the Project's Collaborating Organizations

List Of Figures

LIST OF FIGURES

Figure 2-1: Global – Pediatric (Infant) Vaccines Market (Billion US\$), 2011 – 2016

Figure 2-2: Global – Forecast for Pediatric (Infant) Vaccines Market (Billion US\$), 2017 – 2022

Figure 4-1: Global – Pediatric (Infant) Immunized (Million), 2011 - 2016

Figure 4-2: Global – Forecast for Pediatric (Infant) Immunized (Million), 2017 – 2022

Figure 6-1: Global – Doses of Pediatric (Infant) Vaccines Administered (Million), 2011 - 2016

Figure 6-2: Global – Forecast for Doses of Pediatric (Infant) Vaccines Administered (Million), 2017 - 2022

Figure 8-1: Global – Key Players Vaccines Market Share (Percent), 2011 - 2016

Figure 8-2: Global – Forecast for Key Players Vaccines Market Share (Percent), 2017 - 2022

Figure 9-1: Influenza – Pediatric (Infant) Vaccines Market (Million US\$), 2011 - 2016

Figure 9-2: Influenza – Forecast for Pediatric (Infant) Vaccines Market (Million US\$), 2017 - 2022

Figure 9-3: MMR – Pediatric (Infant) Vaccines Market (Million US\$), 2011 – 2016

Figure 9-4: MMR – Forecast for Pediatric (Infant) Vaccines Market (Million US\$), 2017 - 2022

Figure 9-5: Pneumococcal – Pediatric (Infant) Vaccines Market (Billion US\$), 2011 - 2016

Figure 9-6: Pneumococcal – Forecast for Pediatric (Infant) Vaccines Market (Billion US\$), 2017 - 2022

Figure 9-7: Areas with frequent epidemics of meningococcal meningitis

Figure 9-8: Meningococcal – Pediatric (Infant) Vaccines Market (Million US\$), 2011 - 2016

Figure 9-9: Meningococcal – Forecast for Pediatric (Infant) Vaccines Market (Million US\$), 2017 - 2022

Figure 9-10: Hepatitis – Pediatric (Infant) Vaccines Market (Million US\$), 2011 - 2016

Figure 9-11: Hepatitis – Forecast for Pediatric (Infant) Vaccines Market (Million US\$), 2017 - 2022

Figure 9-12: DTaP – Pediatric (Infant) Vaccines Market (Million US\$), 2011 - 2016

Figure 9-13: DTaP – Forecast for Pediatric (Infant) Vaccines Market (Million US\$), 2017 - 2022

Figure 9-14: Haemophilus Influenzae Type B (HIB) – Vaccines Market (Million US\$), 2011 - 2016

Figure 9-15: Haemophilus Influenzae Type B (HIB) – Forecast for Vaccines Market (Million US\$), 2017 - 2022

Figure 9-16: Combos (Combination) – Vaccines Market (Billion US\$), 2011 - 2016

Figure 9-17: Combos (Combination) – Forecast for Vaccines Market (Billion US\$), 2017 - 2022

Figure 9-18: Polio – Vaccines Market (Million US\$), 2011 - 2016

Figure 9-19: Polio – Forecast for Vaccines Market (Million US\$), 2017 - 2022

Figure 9-20: Rotavirus Deaths Under Five Years of Age per 100 000 Population 5 Years of Age, 2013

Figure 9-21: Ten Countries Accounting for Almost Two Thirds of All Deaths, 2013

Figure 9-22: Rotavirus – Vaccines Market (Million US\$), 2011 - 2016

Figure 9-23: Rotavirus – Forecast for Vaccines Market (Million US\$), 2017 - 2022

Figure 9-24: Varicella – Vaccines Market (Billion US\$), 2011 - 2016

Figure 9-25: Varicella – Forecast for Vaccines Market (Billion US\$), 2017 – 2022

Figure 10-1: Influenza – Number of Infants Immunized (Thousand), 2011 - 2016

Figure 10-2: Influenza – Forecast for Number of Infants Immunized (Thousand), 2017 - 2022

Figure 10-3: MMR – Number of Pediatric (Infants) Immunized (Thousand), 2011 - 2016

Figure 10-4: MMR – Forecast for Number of Pediatric (Infants) Immunized (Thousand), 2017 - 2022

Figure 10-5: Pneumococcal – Number of Infants Immunized (Thousand), 2011 - 2016

Figure 10-6: Pneumococcal – Forecast for Number of Infants Immunized (Thousand), 2011 - 2016

Figure 10-7: Meningococcal – Number of Infants Immunized (Thousand), 2011 - 2016

Figure 10-8: Meningococcal – Forecast for Number of Infants Immunized (Thousand), 2017 - 2022

Figure 10-9: Hepatitis – Number of Infants Immunized (Thousand), 2011 - 2016

Figure 10-10: Hepatitis – Forecast for Number of Infants Immunized (Thousand), 2017 - 2022

Figure 10-11: DTaP – Number of Infants Immunized (Thousand), 2011 - 2016

Figure 10-12: DTaP – Forecast for Number of Infants Immunized (Thousand), 2017 - 2022

Figure 10-13: Hib (Haemophilus Influenzae Type B) – Number of Infants Immunized (Million), 2011 - 2016

Figure 10-14: Hib (Haemophilus Influenzae Type B) – Forecast for Number of Infants Immunized (Million), 2017 - 2022

Figure 10-15: Combos (Combination Vaccines) – Number of Infants Immunized (Million), 2011 - 2016

Figure 10-16: Combos (Combination Vaccines) – Forecast for Number of Infants

Immunized (Million), 2017 - 2022

Figure 10-17: Polio – Number of Infants Immunized (Million), 2011 - 2016

Figure 10-18: Polio – Forecast for Number of Infants Immunized (Million), 2017 - 2022

Figure 10-19: Rotavirus – Number of Infants Immunized (Million), 2011 - 2016

Figure 10-20: Rotavirus – Forecast for Number of Infants Immunized (Million), 2017 - 2022

Figure 10-21: Varicella – Number of Infants Immunized (Million), 2011 - 2016

Figure 10-22: Varicella – Forecast for Number of Infants Immunized (Million), 2017 - 2022

Figure 11-1: Influenza – Doses of Infant Vaccines Administered (Million), 2011 - 2016

Figure 11-2: Influenza – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022

Figure 11-3: MMR – Doses of Infant Vaccines Administered (Million), 2011 - 2016

Figure 11-4: MMR – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022

Figure 11-5: Pneumococcal – Doses of Infant Vaccines Administered (Million), 2011 - 2016

Figure 11-6: Pneumococcal – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022

Figure 11-7: Meningococcal – Doses of Infant Vaccines Administered (Million), 2011 - 2016

Figure 11-8: Meningococcal – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022

Figure 11-9: Hepatitis – Doses of Infant Vaccines Administered (Million), 2011 - 2016

Figure 11-10: Hepatitis – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022

Figure 11-11: DTaP – Doses of Infant Vaccines Administered (Million), 2011 - 2016

Figure 11-12: DTaP – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022

Figure 11-13: Hib (Haemophilus Influenzae Type B) – Doses of Infant Vaccines Administered (Million), 2011 - 2016

Figure 11-14: Hib (Haemophilus Influenzae Type B) – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022

Figure 11-15: Polio – Doses of Infant Vaccines Administered (Million), 2011 - 2016

Figure 11-16: Polio – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022

Figure 11-17: Rotavirus – Doses of Infant Vaccines Administered (Million), 2011 - 2016

Figure 11-18: Rotavirus – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022

Figure 11-19: Varicella – Doses of Infant Vaccines Administered (Million), 2011 - 2016

Figure 11-20: Varicella – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022

Figure 12-1: Worldwide Immunization Coverage (%) in Infants, 2005- 2010

Figure 12-2: Worldwide Immunization Coverage (%) in Infants, 2011- 2015

Figure 13-1: GlaxoSmithKline, plc.'s Vaccines Sales (Billion US\$), 2011 - 2016

Figure 13-2: Forecast for GlaxoSmithKline, plc.'s Vaccines Sales (Billion US\$), 2017 - 2022

Figure 13-3: Merck & Co. Vaccines Sales (Billion US\$), 2011 - 2016

Figure 13-4: Worldwide – Forecast for Merck & Co. Vaccines Sales (Billion US\$), 2017 - 2022

Figure 13-5: Sanofi Pasteur's Vaccines Sales (Billion US\$), 2011 - 2022

Figure 13-6: Forecast for Sanofi Pasteur's Vaccines Sales (Billion US\$), 2017 - 2022

Figure 13-7: Pfizer, Inc.'s Vaccines Sales (Billion US\$), 2011 - 2016

Figure 13-8: Forecast for Pfizer, Inc.'s Vaccines Sales (Billion US\$), 2017 - 2022

Figure 13-9: Others Vaccines Sales (Billion US\$), 2011 - 2016

Figure 13-10: Forecast for Others Vaccines Sales (Billion US\$), 2017 - 2022

Figure 14-1: GSK Vaccine Product Pipeline

Figure 17-1: Countries with HPV Vaccination Program listed on their National Immunization Program (NIP) Schedule

Figure 17-2: Number of Cases of Diphtheria, Pertussis, Tetanus & Measles by Major Region Worldwide, 2013

Figure 17-3: Vaccines Procured by UNICEF: Industrialized and Emerging Market Country Manufacturers

Figure 17-4: Vaccines procured by UNICEF: Industrialized and Emerging Market Country Manufacturers

Figure 17-5: US Retail Clinics Expected to Surge by 2017

I would like to order

Product name: Pediatric Vaccines Market, Doses, Immunization, Cases and Forecast: Worldwide Analysis

Product link: <https://marketpublishers.com/r/P30680D4053EN.html>

Price: US\$ 1,700.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P30680D4053EN.html>